ZimVie Inc (ZIMV) AI Stock Analysis

• Market Cap: $527.92M
• Dividend Yield: N/A
• Average Volume (3M): 673.81K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.55
• Revenue Growth: -32.70%
• EPS Growth: 94.89%
• Country: US
• Employees: 1,770
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Devices
• EPS (TTM): 0.27
• Shares Outstanding: 28,200,941
• 10 Day Avg. Volume: 1,750,926
• 30 Day Avg. Volume: 673,807
• PEG Ratio: -0.39
• Price to Book (P/B): 0.62
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 34.42
• Enterprise Value/Market Cap: 0.79
• Enterprise Value/Revenue: 0.22
• Enterprise Value/Gross Profit: 1.44
• Enterprise Value/Ebitda: 2.57
• 1Y Price Target: $15.00
• Price Target Upside: -19.87% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 4

• Rating: 67 Neutral
• Price Target: $20.50 ▲(9.51%Upside)

ZimVie's overall stock score reflects a mix of challenges and opportunities. The acquisition by ARCHIMED at a premium is a major positive factor, providing potential future stability and growth. However, ongoing financial performance issues, such as declining revenue and profitability challenges, weigh down the score. Technical indicators show bullish momentum, but caution is advised due to overbought signals. Valuation remains a concern due to negative earnings.

Positive Factors

Acquisition

ZIMV announced an agreement to be acquired by ARCHIMED for an enterprise value of $730M, translating to $19 per share.

Market Outlook

Guidance provided during the conference suggests a favorable outlook for the company's performance.

Revenue and Margins

The acquisition of a distributor in Costa Rica for $3.3M should be accretive to revenue and margins.

Negative Factors

Cost Structure

Tariffs were mentioned as a factor that could impact the company's cost structure.

Product Performance

Implants and scanners were the two weakest product groups in the quarter.

Revenue Performance

ZIMV missed consensus revenue while adjusted EBITDA beat expectations in 1Q25.

ZimVie Inc Business Overview & Revenue Model

Company Description

ZimVie Inc., a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies. The company also provides MIS solutions, such as Vital MIS and Timberline; and motion preservation solutions, including Mobi-C and The Tether. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.

How the Company Makes Money

ZimVie Inc makes money by selling its medical technology products and solutions primarily in the dental and spine markets. The company's revenue model is based on direct sales to healthcare providers, hospitals, and clinics, where it offers a range of products such as dental implants, biomaterials, and digital dentistry solutions. Additionally, ZimVie generates income through the sale of spinal fusion and fixation devices, which are used by surgeons and healthcare facilities in various spinal surgeries. The company may also benefit from strategic partnerships and collaborations that expand its market reach and product offerings, contributing to its overall earnings.

ZimVie Inc Financial Statement Overview

Summary

ZimVie Inc. faces challenges with declining revenues and negative profit margins, despite improvements in cash flow and equity ratio. High leverage and ongoing profitability issues necessitate focus on operational efficiency and revenue growth.

Income Statement

ZimVie Inc. has struggled with declining revenues, from $1,014.6 million in 2021 to $443.6 million in TTM. The net profit margin is negative, indicating ongoing losses, though there is a slight improvement in EBITDA margin in TTM. This reflects challenges in maintaining both revenue levels and profitability.

Balance Sheet

The debt-to-equity ratio is relatively high at approximately 0.59 in TTM, indicating significant leverage. However, the equity ratio has improved to 52.97%, showing moderate financial stability. The company’s ROE remains negative, suggesting inefficiencies in generating returns on equity.

Cash Flow

The company has managed a positive free cash flow in TTM, although it has decreased from previous periods. Operating cash flow to net income ratio is not favorable due to negative net income, but cash flow management shows some resilience.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	443.55M	449.75M	457.43M	913.86M	1.01B	912.40M
Gross Profit	287.56M	287.45M	290.38M	613.08M	628.80M	599.50M
EBITDA	36.95M	29.61M	91.07M	79.16M	28.70M	-86.70M
Net Income	-19.54M	-25.82M	-393.28M	-63.88M	-95.30M	-179.00M
Balance Sheet
Total Assets	745.78M	753.67M	1.21B	1.64B	1.83B	1.95B
Cash, Cash Equivalents and Short-Term Investments	66.75M	74.97M	71.51M	89.60M	100.40M	27.40M
Total Debt	232.71M	232.57M	521.93M	564.14M	57.90M	89.20M
Total Liabilities	350.66M	371.97M	795.85M	883.45M	375.30M	458.70M
Stockholders Equity	395.12M	381.71M	409.49M	758.60M	1.45B	1.49B
Cash Flow
Free Cash Flow	5.74M	7.49M	24.66M	-1.92M	7.70M	47.70M
Operating Cash Flow	11.77M	14.17M	37.15M	24.63M	64.30M	86.00M
Investing Cash Flow	284.49M	282.30M	-15.17M	-28.66M	-60.30M	-49.50M
Financing Cash Flow	-294.36M	-294.67M	-25.67M	-1.31M	72.30M	-46.50M

ZimVie Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 18.72
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZIMV, the sentiment is Positive. The current price of 18.72 is above the 20-day moving average (MA) of 11.65, above the 50-day MA of 10.03, and above the 200-day MA of 12.12, indicating a bullish trend. The MACD of 2.33 indicates Negative momentum. The RSI at 86.83 is Negative, neither overbought nor oversold. The STOCH value of 97.78 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ZIMV.

ZimVie Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PODD	80 Outperform	$20.42B	52.23	37.92%	―	23.49%	71.25%
ZBH	74 Outperform	$19.30B	21.62	7.31%	0.98%	3.30%	-2.39%
STE	71 Outperform	$22.67B	36.32	9.46%	0.99%	0.32%	64.36%
ZIMV	67 Neutral	$527.92M	―	-6.35%	―	-32.70%	94.89%
LIVN	61 Neutral	$2.38B	30.62	-19.69%	―	7.97%	-592.40%
OFIX	51 Neutral	$441.57M	―	-27.82%	―	5.85%	-8.92%
Sector *	46 Neutral	C$204.55M	-3.23	-23.14%	1.87%	20.75%	-0.36%

ZimVie Inc Corporate Events

ZimVie Inc to be Acquired by ARCHIMED

On July 21, 2025, ZimVie Inc. announced a definitive agreement to be acquired by ARCHIMED, an investment firm focused on healthcare industries, for $19.00 per share in cash, valuing the company at approximately $730 million. The transaction, which represents a 99% premium over ZimVie’s 90-day volume-weighted average price, is expected to close by the end of 2025, pending customary closing conditions and stockholder approval. The merger agreement includes a ‘Go-Shop’ period allowing ZimVie to solicit alternative acquisition proposals until August 29, 2025. Upon completion, ZimVie will become a privately held company, and its shares will no longer be listed on NASDAQ.

The most recent analyst rating on (ZIMV) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on ZimVie Inc stock, see the ZIMV Stock Forecast page.

ZimVie Inc Holds Annual Shareholders Meeting

ZimVie Inc. held its annual shareholders meeting on May 7, 2025, where key decisions were made regarding company governance and executive compensation. Shareholders elected a Class III director, ratified PricewaterhouseCoopers LLP as the independent auditor for 2025, and approved the executive compensation plan on a non-binding advisory basis.

The most recent analyst rating on (ZIMV) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on ZimVie Inc stock, see the ZIMV Stock Forecast page.

ZimVie Inc Reports Q1 2025 Financial Results

On May 8, 2025, ZimVie Inc. reported its financial results for the first quarter of 2025, showing net sales of $112.0 million, which marked a 5.2% decrease compared to the same period in 2024. Despite a net loss of $2.6 million, the company improved its net loss margin significantly from the previous year. Adjusted EBITDA increased to $17.6 million, reflecting a 15.7% margin. The company remains focused on operational efficiency and profitability improvements, aiming for a return to top-line growth.